TIDMMEDG 
 
RNS Number : 1605N 
Medgenics Inc 
07 June 2010 
 

                                Medgenics, Inc. 
                         ('Medgenics' or the 'Company') 
 
               Directors Dealing and Block Listing interim review 
                                                                     7 June 2010 
 
Medgenics was informed on 3 June 2010 that Deborah Pearlman, the spouse of 
Andrew Pearlman, a director of the Company, had on 31 May 2010 given notice that 
she wished to exercise 3,166 RW Warrants for common shares of par value of US 
$0.0001 each ("Common Shares") at an exercise price of US $0.0000047 per Common 
Share. Following the issue of said Common Shares on 3 June 2010, Andrew Pearlman 
is interested in 1,238,185 Common Shares representing 0.8% of the Company's 
issued share capital. 
 
1. Name of company: 
 
Medgenics, Inc. 
 
2. Name of scheme: 
 
Warrants and Options under the Company's Share Incentive Schemes 
 
3. Period of return:                  From 
                              To 
4 December 2009                                               3 June 2010 
 
4. Number and class of securities not issued under the scheme at the beginning 
of the period: 
 
6,634,015  Common Shares 
 
5. Number of securities issued under scheme during period: 
 
235,238 Common Shares following the due exercise of Warrants issued by the 
Company (213,675 Common Shares pursuant to W Warrants and 21,563 Common Shares 
pursuant to RW Warrants). 
 
6. Balance under scheme of securities not yet issued at end of period: 
 
6,398,777 Common Shares 
 
7. Number and class of securities originally admitted and the date of admission: 
 
20,818,683 Common Shares admitted under the block admission on 4 December 2007. 
 
Following the above issues during the period the total number of Common Shares 
in issue is 154,877,554 .The percentage of shares not in public hands is 29.2 
per cent. There are no changes in the shareholders who hold more than three per 
cent of  the issued share capital as previously announced on May 25, 2010. 
 
 
For further information, contact: 
 
Andrew Pearlman                                             +972 4 902 8900 
CEO 
Medgenics, Inc 
 
Mike Wort / Anna Dunphy                                 +44 207 861 3838 
De Facto Communications (PR) 
 
James Pinner / Derek Crowhurst                        +44 207 444 0800 
Religare Capital Markets  (Nomad) 
 
Ian Callaway / Alex Mattey                               +44 207 638 5600 
SVS Securities plc (Joint Broker) 
 
Jonathan Senior                                                 +44 207 776 1219 
Nomura Code (Joint Broker) 
 
 
Notes to Editors: 
About Medgenics: 
Medgenics is a commercial -stage biopharmaceutical Company developing its unique 
tissue-based Biopump platform technology to provide sustained-action protein 
therapy for the treatment of a range of chronic diseases. The first revenue 
generating commercial deal with a well known multinational pharmaceutical 
company was negotiated in late 2009 and we look forward to generating additional 
deals to further commercialise the Biopump platform technology. 
Biopumps are made using needle biopsies taken from the lower layer of the 
patient's skin under local anaesthetic, and processed during 10-14 days to 
become 30 mm long tissue biofactories producing the required protein.  The 
requisite number of Biopumps are injected under the patient's skin to provide 
sustained protein production and delivery for many months. The Company is 
developing the Biopump to provide substantially greater safety and reliability 
in protein treatment in a more cost effective manner than experienced with the 
existing injected protein therapies.  Medgenics currently has three products in 
development based on this technology and addressing the indications of: 
 
 - Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO) 
- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a) 
- Haemophilia - using a Biopump to produce clotting Factor VIII 
The Company's Phase I/II clinical trial using EPODURE to treat anaemia in 
patients with chronic kidney disease, has demonstrated proof of concept of the 
Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for 
six months or more, EPODURE Biopumps have already provided effective anaemia 
treatment in most of these patients for 6-12 months, even at the low 
administered dose. 
Medgenics intends to develop its innovative products and bring them to market 
via multiple strategic partnerships with major pharmaceutical and/or medical 
device companies. In addition to treatments for Anaemia, Hepatitis-C, and 
Haemophilia, Medgenics plans to develop and/or out-license a pipeline of future 
Biopump products targeting the large and rapidly growing global protein therapy 
market, which is forecast to reach US $87 billion by 2010. Other potential 
applications of Biopumps producing various proteins include multiple sclerosis, 
arthritis, pediatric growth hormone deficiency, obesity, and diabetes. 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RDSKKODPFBKKBAK
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Medgenics(Regs) Charts.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Medgenics(Regs) Charts.